{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:02:56Z","timestamp":1790899376004,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ijid.2017.01.028","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T07:30:28Z","timestamp":1486107028000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"C","title":["Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm"],"prefix":"10.1016","volume":"56","author":[{"given":"Martin","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Maeurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2017.01.028_bib0005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/emmm.201100165","article-title":"PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells","volume":"3","author":"Karwacz","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12026-014-8524-1","article-title":"Regulation of T cell responses by the receptor molecule Tim-3","volume":"59","author":"Gorman","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.ijid.2017.01.028_bib0020","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ijid.2017.01.028_bib0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0045","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1158\/0008-5472.CAN-07-6598","article-title":"Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1\/PD-1 axis and transforming growth factor beta","volume":"68","author":"Wei","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijid.2017.01.028_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cellimm.2014.02.007","article-title":"Correlations of programmed death 1 expression and serum IL-6 level with exhaustion of cytomegalovirus-specific T cells after allogeneic hematopoietic stem cell transplantation","volume":"288","author":"Kato","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijid.2017.01.028_bib0060","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2017.01.028_bib0065","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ijid.2017.01.028_bib0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4049\/jimmunol.181.1.116","article-title":"Programmed death (PD)-1:PD-ligand 1\/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis","volume":"181","author":"Jurado","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0080","doi-asserted-by":"crossref","first-page":"20078","DOI":"10.7448\/IAS.18.1.20078","article-title":"Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients","volume":"18","author":"Sada-Ovalle","year":"2015","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"10.1016\/j.ijid.2017.01.028_bib0085","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/infdis\/jiv238","article-title":"Dysregulation of apoptosis is a risk factor for tuberculosis disease progression","volume":"212","author":"Elliott","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0090","doi-asserted-by":"crossref","first-page":"e0137646","DOI":"10.1371\/journal.pone.0137646","article-title":"PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment","volume":"10","author":"Hassan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.01.028_bib0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/infdis\/jit206","article-title":"Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis","volume":"208","author":"Singh","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0100","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/eji.201141421","article-title":"Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis","volume":"41","author":"McNab","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0105","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/IAI.06018-11","article-title":"Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection","volume":"80","author":"Kee","year":"2012","journal-title":"Infection Immun"},{"key":"10.1016\/j.ijid.2017.01.028_bib0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tube.2014.01.005","article-title":"Programmed death-1 receptor suppresses gamma-IFN producing NKT cells in human tuberculosis","volume":"94","author":"Singh","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0115","doi-asserted-by":"crossref","first-page":"e44728","DOI":"10.1371\/journal.pone.0044728","article-title":"Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-gamma producing T cells","volume":"7","author":"Singh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.01.028_bib0120","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.5588\/ijtld.15.0148","article-title":"Enrichment of regulatory T-cells in blood of patients with multidrug-resistant tuberculosis","volume":"19","author":"Li","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0125","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1086\/654932","article-title":"Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis","volume":"202","author":"Alvarez","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0130","doi-asserted-by":"crossref","first-page":"e36046","DOI":"10.1371\/journal.pone.0036046","article-title":"Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis","volume":"7","author":"Adekambi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.01.028_bib0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4161\/onci.20823","article-title":"PD-1 and BTLA and CD8(+) T-cell exhaustion \u201cin cancer\u201d: \u201cexercising\u201d an alternative viewpoint","volume":"1","author":"Haymaker","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijid.2017.01.028_bib0140","doi-asserted-by":"crossref","first-page":"e1004603","DOI":"10.1371\/journal.ppat.1004603","article-title":"Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization","volume":"11","author":"Gideon","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2017.01.028_bib0145","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2017.01.028_bib0150","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0155","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0160","doi-asserted-by":"crossref","first-page":"e1005270","DOI":"10.1371\/journal.ppat.1005270","article-title":"PD-L1 blockade differentially impacts regulatory T cells from HIV-infected individuals depending on plasma viremia","volume":"11","author":"Peligero","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2017.01.028_bib0165","doi-asserted-by":"crossref","first-page":"e0124659","DOI":"10.1371\/journal.pone.0124659","article-title":"Attrition of TCR Valpha7.2+ CD161+\u2009+ MAIT cells in HIV\u2014tuberculosis co-infection is associated with elevated levels of PD-1 expression","volume":"10","author":"Saeidi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.01.028_bib0170","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4049\/jimmunol.1202438","article-title":"Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion","volume":"190","author":"Illingworth","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0175","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.celrep.2013.11.002","article-title":"PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria","volume":"5","author":"Horne-Debets","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijid.2017.01.028_bib0180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.celrep.2015.09.004","article-title":"Circulating Th1-cell-type Tfh cells that exhibit impaired B cell help are preferentially activated during acute malaria in children","volume":"13","author":"Obeng-Adjei","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijid.2017.01.028_bib0185","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.immuni.2009.03.003","article-title":"Follicular helper T cells: lineage and location","volume":"30","author":"Fazilleau","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.ijid.2017.01.028_bib0190","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI33402","article-title":"Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection","volume":"118","author":"Lopes","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijid.2017.01.028_bib0195","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0200","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1128\/JVI.02474-07","article-title":"High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome","volume":"82","author":"Kasprowicz","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0205","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/ajt.12480","article-title":"PD-1 analysis on CD28(\u2212) CD27(\u2212) CD4\u2009T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients","volume":"13","author":"Dirks","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2017.01.028_bib0210","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1158\/0008-5472.CAN-05-1098","article-title":"High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients","volume":"65","author":"Schmitz-Winnenthal","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijid.2017.01.028_bib0215","doi-asserted-by":"crossref","first-page":"40836","DOI":"10.18632\/oncotarget.5696","article-title":"Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases","volume":"6","author":"Harter","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijid.2017.01.028_bib0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1128\/JVI.01181-09","article-title":"Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection","volume":"84","author":"Sadagopal","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0225","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/cas.12502","article-title":"PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer","volume":"105","author":"Waki","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ijid.2017.01.028_bib0230","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-13-0133","article-title":"PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection","volume":"2","author":"MacFarlane","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijid.2017.01.028_bib0235","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.chom.2015.03.007","article-title":"PD-1 co-inhibitory and OX40 co-stimulatory crosstalk regulates helper T cell differentiation and anti-Plasmodium humoral immunity","volume":"17","author":"Zander","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijid.2017.01.028_bib0240","doi-asserted-by":"crossref","first-page":"451694","DOI":"10.1155\/2011\/451694","article-title":"The PD-1\/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion","volume":"2011","author":"Hofmeyer","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0245","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2017.01.028_bib0250","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ijid.2017.01.028_bib0255","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2217\/imt.15.57","article-title":"Antibody-based immunotherapy of solid cancers: progress and possibilities","volume":"7","author":"Nicodemus","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijid.2017.01.028_bib0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijid.2017.01.028_bib0265","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.drudis.2015.07.003","article-title":"Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies","volume":"20","author":"Borch","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijid.2017.01.028_bib0270","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0275","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2017.01.028_bib0280","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2017.01.028_bib0285","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0290","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ijid.2017.01.028_bib0295","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/joim.12256","article-title":"Inflammation and tuberculosis: host-directed therapies","volume":"277","author":"Zumla","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0300","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/eji.201343680","article-title":"Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection","volume":"44","author":"Bandaru","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0305","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-015-0144-x","article-title":"Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options","volume":"12","author":"Velu","year":"2015","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.ijid.2017.01.028_bib0310","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00281-015-0531-3","article-title":"Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis","volume":"38","author":"Dorhoi","year":"2015","journal-title":"Semin Immunopathol"},{"issue":"4","key":"10.1016\/j.ijid.2017.01.028_bib0315","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1473-3099(15)70008-3","volume":"15","author":"Ravimohan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0320","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2017.01.028_bib0325","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.01.028_bib0330","doi-asserted-by":"crossref","first-page":"e1002504","DOI":"10.1371\/journal.ppat.1002504","article-title":"The CTLA-4 and PD-1\/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology","volume":"8","author":"Hafalla","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2017.01.028_bib0335","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.2180","article-title":"Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection","volume":"13","author":"Butler","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0340","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijid.2017.01.028_bib0345","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0350","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0355","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0360","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijid.2017.01.028_bib0365","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijid.2017.01.028_bib0370","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijid.2017.01.028_bib0375","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","article-title":"Chemotherapy use, performance status, and quality of life at the end of life","volume":"1","author":"Prigerson","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0380","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0385","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.molimm.2015.02.009","article-title":"Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy","volume":"67","author":"Swaika","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0390","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0395","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.humpath.2011.10.014","article-title":"CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.ijid.2017.01.028_bib0400","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bjc.2015.412","article-title":"Melanoma-expressed CD70 is involved in invasion and metastasis","volume":"114","author":"Pich","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijid.2017.01.028_bib0405","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/QAD.0000000000000779","article-title":"Increased extrafollicular expression of the B-cell stimulatory molecule CD70 in HIV-1-infected individuals","volume":"29","author":"Lantto","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2017.01.028_bib0410","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/leu.2014.84","article-title":"TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ijid.2017.01.028_bib0415","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/mabs.27398","article-title":"ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade","volume":"6","author":"Silence","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.ijid.2017.01.028_bib0420","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20050121","article-title":"Cellular immune selection with hepatitis C virus persistence in humans","volume":"201","author":"Cox","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0425","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1128\/JVI.01472-10","article-title":"CAPRISA study team. Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression","volume":"84","author":"Mlotshwa","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0430","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1093\/cid\/civ615","article-title":"T-cell therapy: options for infectious diseases","volume":"61","author":"Parida","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0435","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijid.2015.01.016","article-title":"Cellular therapy in tuberculosis","volume":"32","author":"Parida","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.028_bib0440","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2017.01.028_bib0445","doi-asserted-by":"crossref","first-page":"656340","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0450","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0455","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.molimm.2011.06.436","article-title":"PD-L2 is expressed on activated human T cells and regulates their function","volume":"48","author":"Messal","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0460","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2006-09-044826","article-title":"PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors","volume":"109","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2017.01.028_bib0465","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1572-0241.2006.00948.x","article-title":"Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases","volume":"102","author":"Mataki","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0470","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.07.016","article-title":"PD-1 ligand expression by human colonic myofibroblasts\/fibroblasts regulates CD4+ T-cell activity","volume":"135","author":"Pinchuk","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2017.01.028_bib0475","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy","volume":"2","author":"McDermott","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijid.2017.01.028_bib0480","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","article-title":"The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies","volume":"6","author":"Shi","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijid.2017.01.028_bib0485","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D\u2019Incecco","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijid.2017.01.028_bib0490","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ijid.2017.01.028_bib0495","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","article-title":"Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma","volume":"51","author":"Ritprajak","year":"2015","journal-title":"Oral Oncol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217300310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217300310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T07:23:26Z","timestamp":1658561006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971217300310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":99,"alternative-id":["S1201971217300310"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2017.01.028","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2017.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}